PCSK9 inhibitors - Past, present and future

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 10, 2015, Pages 1517-1521

  Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

alirocumab; bococizumab; cardiovascular disease prevention; evolocumab; low density lipoprotein cholesterol; PCSK9 inhibitors; statins

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; BOCOCIZUMAB; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; GAIN OF FUNCTION MUTATION; HEART INFARCTION; HUMAN; HYPOCHOLESTEROLEMIA; REVIEW; UNSTABLE ANGINA PECTORIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84941993216     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1075506     Document Type: Review

References (22)

1. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818
2. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013; 10: 453-64
3. Reiner Ž, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J 2013; 54: 339-45
4. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35: 960-8
5. Reiner Ž. A comparison of European and US guidelines for familial hypercholestrolaemia. Curr Opin Lipidol 2015; 26: 215-20
6. Reiner Ž. Similarities and differences between European and united States guidelines for the management of dyslipidaemias. Kardiol Polska 2015; 7. 73: 9
7. Reiner Ž. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014; 24: 1057-66
8. Reiner Ž. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015. [Epub ahead of print]
9. Šimić I, Reiner Ž. Adverse effects of statins-myths and reality. Curr Pharm Des 2015; 21: 1220-6
10. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-22
11. Reiner Ž, De Bacquer D, Kotseva K, et al. EUROASPIRE III Study Group. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. Atherosclerosis 2013; 231: 300-7
12. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6
13. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-23
14. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72
15. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19
16. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Intern Med 2015; 163: 40-51
17. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29-36
18. Koren MJ, Roth EM, McKenney JM, et al. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: a Phase II pooled analysis. Postgrad Med 2015; 127: 125-32
19. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99
20. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9
21. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 341-50
22. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115: 1212-21